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Because both ovarian and breast cancer are hormone-related and are known to have some predisposition
genes in common, we evaluated 11 of the most significant hits (six with confirmed associations with
breast cancer) from the breast cancer genome-wide association study for association with invasive ovarian
cancer. Eleven SNPs were initially genotyped in 2927 invasive ovarian cancer cases and 4143 controls from
six ovarian cancer case–control studies. Genotype frequencies in cases and controls were compared using a
likelihood ratio test in a logistic regression model stratified by study. Initially, three SNPs (rs2107425 in
MRPL23, rs7313833 in PTHLH, rs3803662 in TNRC9) were weakly associated with ovarian cancer risk and
one SNP (rs4954956 in NXPH2) was associated with serous ovarian cancer in non-Hispanic white subjects
(P-trend < 0.1). These four SNPs were then genotyped in an additional 4060 cases and 6308 controls from
eight independent studies. Only rs4954956 was significantly associated with ovarian cancer risk both in
the replication study and in combined analyses. This association was stronger for the serous histological
subtype [per minor allele odds ratio (OR) 1.07 95% CI 1.01–1.13, P-trend 5 0.02 for all types of ovarian
cancer and OR 1.14 95% CI 1.07–1.22, P-trend 5 0.00017 for serous ovarian cancer]. In conclusion, we
found that rs4954956 was associated with increased ovarian cancer risk, particularly for serous ovarian
cancer. However, none of the six confirmed breast cancer susceptibility variants we tested was associated
with ovarian cancer risk. Further work will be needed to identify the causal variant associated with
rs4954956 or elucidate its function.
INTRODUCTION
Recent advances in high-throughput genotyping technologies
have enabled rapid and efficient genotyping to be performed
for hundreds of thousands of genetic variants without prior
knowledge of gene function as part of genome-wide association
studies (GWAS). Several GWAS have led to the identification
of novel loci for many different common complex diseases,
including diabetes, Crohn’s disease, rheumatoid arthritis and
breast, prostate and colorectal cancers, confirming that suscep-
tibility to these diseases has a polygenic component (1–4). The
known ovarian cancer susceptibility genes, such as BRCA1 and
BRCA2, appear to explain ,40% of the excess familial risk of
this disease (5). It is likely that a combination of multiple low or
moderate penetrance genetic variants contribute to the remain-
ing unexplained excess ovarian cancer risks. It is evident that
some loci regulate carcinogenic pathways common to multiple
cancers, for example, the variant rs6983267 in 8q24 is associ-
ated with colorectal, prostate and ovarian cancer risk (6).
Also, BRCAC1 and BRCA2 gene mutations are associated
with the variation in the risks of both breast and ovarian
cancers. The development of breast and ovarian cancers both
have a hormonal basis of female cancers, therefore, it seems
logical to hypothesize that these malignancies share some
common genetic risks and that breast cancer susceptibility
loci may also be associated with the risk of ovarian cancer.
The aim of this study is to evaluate whether the 11 SNPs
that were most strongly associated with breast cancer risk in
our breast cancer GWAS (7) were associated with epithelial
ovarian cancer (EOC) risk in 14 case–control studies which
comprised 6987 invasive EOC cases and 10451 controls.
This represents the largest ovarian cancer case–control analy-
sis conducted to date. These 11 SNPs included six breast
cancer susceptibility variants that reach genome-wide signifi-
cance (P , 1028) [i.e. rs2981582 (FGFR2), rs12443621
(TNRC9), rs13281615 (8q), rs3817198 (LSP1), rs3803662
(TNRC9) and rs889312 (MAP3K1)]. The remaining five top
hits from breast cancer GWAS, namely rs4666451 (located
on chromosome 2p), rs2107425 (MRPL23), rs7313833
(PTHLH), rs981782 (on chromosome 5p) and rs4954956
(NXPH2) are also strong candidate for breast cancer associ-
ations (P , 1025).
RESULTS
We have genotyped the 11 SNPs identified through our
GWAS for breast cancer in a set of six ovarian cancer
case–control studies. Genotype distributions in controls were
consistent with Hardy–Weinberg equilibrium (HWE) except
for rs4666451 in the USC (P ¼ 0.02) and UKO study
(P ¼ 0.01) and rs7313833 in the AUS study (P ¼ 0.04).
These deviations are likely to be due to chance, rather than
a reflection of poor genotyping, because inspection of the
cluster plots indicated good discrimination between genotype;
furthermore deviation from HWE was not observed in cases.
In addition, the genotyping for rs981782 failed in the UKO
study and rs7313833 failed in the GER study.
Genotype-specific odds ratios (ORs) and tests of association
are presented in Table 1. The genotype-specific risks for serous
ovarian cancer, estimated from the combined data, are also pre-
sented in Table 1. The observed genotype frequencies for each
of the data sets are presented in Supplementary Material,
Table S1. There was no association in controls between age and
genotype frequency for any of the SNPs and age-adjusted
genotype-specific risks were similar to the unadjusted ORs
(data not shown). Two SNPs (rs7313833 and rs210742) showed
some evidence of association with all types of invasive ovarian
cancer, whereas rs4954956 and rs210742 showed some evidence
of association with serous type ovarian. The association of
rs3803662 with ovarian cancer risk was of borderline significance
(P ¼ 0.07) with ovarian cancer risks. There was no association
for the remaining seven SNPs (P . 0.1).
Carriers of the minor allele of rs7313833 were at increased
risk of ovarian cancer: per minor allele OR ¼ 1.09, 95% CI
1.01–1.18, P-trend ¼ 0.027. Carriers of the minor allele of
rs2107425 were at decreased risk of ovarian cancer overall
and serous type ovarian cancer: per minor allele OR ¼ 0.91
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95% CI 0.84–0.98 (P ¼ 0.027) and OR ¼ 0.91 95% CI 0.82–
1.00, (P-trend ¼ 0.048), respectively. Carriers of the minor
allele of rs4954956 were at increased risk of serous type
ovarian cancer: per minor allele OR ¼ 1.10 95% CI 1.02–
1.19, (P-trend ¼ 0.01).
The four SNPs (rs2107425, rs3803662, rs4954956 and
rs7313833) with some evidence of association in either all
cases or serous type ovarian cancer were then genotyped in
the validation set. The results of the validation component
alone and in combination with the initial set are presented in
Table 2. SNP rs4954956 (NXPH2) was associated with
overall ovarian cancer risk and with the risk of serous
subtype both in the validation set alone and in the combined
analysis, although the risk was stronger for the serous
subtype (Table 2). The risk for serous ovarian cancer per
minor allele of rs4954956 was 1.17 (95% CI 1.06–1.28,
P ¼ 0.0011) for the validation set and 1.14 (95% CI 1.07–
1.22, P ¼ 0.00017) for the combined analyses. For all types
of ovarian cancer, per minor allele risk for rs4954956 was
1.10 (95% CI 1.02–1.19; P ¼ 0.01) for the validation set
and 1.07 (95% CI 1.01–1.13; P ¼ 0.02) for the combined ana-
lyses. Figure 1 shows the genotype-specific ORs for each
ovarian study and for the combined analysis for rs4954956.
The effect of rs4954956 was slightly attenuated after adjusting
for a first degree family history of breast cancer [per rare allele
OR 1.06, 95% CI 0.97–1.16 (P ¼ 0.17) for all types of
ovarian cancer and 1.10, 95% CI 0.99–1.22 (P ¼ 0.066) for
serous type of ovarian cancer, respectively]. The remaining
three SNPs were not validated. There was no evidence for
between-study heterogeneity (P . 0.05) for all the SNPs
tested except rs3817198 (P ¼ 0.0002) in the initial set.
DISCUSSION
This is the largest ovarian cancer association study conducted
to date involving 14 studies from Ovarian Cancer Association
Consortium (OCAC) and comprising 5876 invasive EOC






cancer, OR (95% CIa)
All type of invasive cases Serous type invasive cases
No.
cases
P-hetb P-trend OR (95% CIc) No.
serous
P-hetb P-trend OR (95% CIc)
rs2981582 FGFR2 0.39 3903 1.26 (1.23–1.30) 2513 0.09 0.46 0.97 (0.90–1.05) 1340 0.24 0.82 0.99 (0.90–1.08)
rs12443621 TNRC9 0.46 3860 1.11 (1.08–1.14) 2464 0.27 0.24 0.96 (0.89–1.03) 1309 0.67 0.53 0.97 (0.89–1.06)
rs13281615 8q 0.40 3892 1.08 (1.05–1.11) 2502 0.85 0.69 0.99 (0.92–1.06) 1331 0.86 0.58 0.97 (0.89–1.07)
rs3817198 LSP1 0.31 3795 1.07 (1.04–1.11) 2479 0.71 0.75 1.01 (0.94–1.09) 1319 0.60 0.94 1.00 (0.90–1.10)
rs889312 MAP3K1 0.28 3897 1.13 (1.10–1.16) 2513 0.93 0.80 1.01 (0.93–1.09) 1336 0.94 0.91 0.99 (0.90–1.10)
rs4666451 2p 0.40 3871 0.97 (0.94–1.00) 2488 0.78 0.55 1.02 (0.95–1.10) 1324 0.83 0.57 1.03 (0.94–1.12)
rs2107425 MRPL23 0.32 3891 0.96 (0.93–0.99) 2504 0.01 0.015 0.91 (0.84–0.98) 1335 0.008 0.048 0.91 (0.82–1.00)
rs7313833 PTHLH 0.33 3865 1.03 (1.00–1.06) 2483 0.06 0.027 1.09 (1.01–1.18) 1327 0.72 0.60 1.03 ((0.94–
1.13)
rs981782 5p 0.47 3657 0.96 (0.93–0.99) 2396 0.55 0.31 1.04 (0.97–1.12) 1279 0.63 0.35 1.04 (0.95–1.14)
rs4954956 NXPH2 0.25 3913 0.97 (0.94–1.00) 2497 0.79 0.50 1.03 (0.95–1.12) 1325 0.13 0.049 1.11 (1.00–1.23)
rs3803662 TNRC9 0.27 3889 1.20 (1.16–1.24) 2527 0.14 0.07 0.92 (0.84–1.01) 1335 0.11 0.10 0.92 (0.83–1.02)
The combined data from the initial stage1 studies of White non-Hispanic subjects. The following studies are included in the initial studies: AUS, SEA,
MAL, STA, UKO and USC.
aReported breast cancer GWAS per allele odds ratio (OR) and 95% CI (7).
bComparison of genotype frequency between cases and controls (2df).
cPer allele odds ratio and 95% CI, data highlighted with bold text are borderline significant (P , 0.1) results.
Table 2. Genotype-specific risks 95% CI for all types and serous type of invasive epithelial ovarian cancer in the validation (stage 2) studies for non-Hispanic
White subjects
SNP Gene/region No. controls Validation studies without initial six studies All studies combined
No. cases P-heta P-trend OR (95% CI)b No. controls No. cases P-heta P-trend OR (95% CI)b
All types of invasive ovarian cancer
rs2107425 MRPL23 4647 2862 0.22 0.21 1.05 (0.97–1.12) 8538 5366 0.07 0.49 0.98 (0.93–1.03)
rs7313833 PTHLH 4575 2896 0.71 0.61 0.98 (0.91–1.05) 8440 5379 0.31 0.22 1.03 (0.98–1.09)
rs4954956 NXPH2 4540 2856 0.03 0.01 1.10 (1.02–1.19) 8453 5353 0.05 0.02 1.07 (1.01–1.13)
rs3803662 TNRC9 5084 3121 0.40 0.82 1.01 (0.94–1.08) 8973 5648 0.54 0.32 0.97 (0.92–1.03)
Serous type ovarian cancer
rs2107425 MRPL23 4647 1611 0.12 0.06 1.09 (1.00–1.19) 8538 2946 0.06 0.91 1.00 (0.94–1.07)
rs7313833 PTHLH 4575 1648 0.35 0.17 0.94 (0.86–1.03) 8440 2975 0.72 0.55 0.98 (0.92–1.04)
rs4954956 NXPH2 4540 1602 0.003 0.001 1.17 (1.06–1.28) 8453 2927 0.0004 0.0002 1.14 (1.07–1.22)
rs3803662 TNRC9 5084 1780 0.44 0.18 1.06 (0.97–1.16) 8973 3115 0.57 0.96 1.00 (0.94–1.07)
The validation studies included: DOV, GER, HAW, HOP, MAY, NCO, POL and UCI. Data highlighted with bold text are significant results (P , 0.05).
aComparison of genotype frequency between cases and controls (2df).
bPer allele Odds ratio and 95% CI.
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cases and 9273 controls of non-Hispanic origin. We observed
an association for the minor allele of SNP rs4954956 with
increased risks of EOC both in the initial set and in the repli-
cation set with the strongest gene-dose effect for serous type
EOC. We urge caution in the interpretation of these results
as a number of reported positive associations in the literature
have not been replicated by the subsequent studies. Indeed, the
proportion of studies with false-positive findings can be as
high as 95% in association studies between genetic variants
and disease risks (8–10). To estimate the likelihood that our
results represent a true association with ovarian cancer risks,
we calculated the false-positive report probability (FPRP)
Figure 1. Genotype-specific risks of SNP rs4954956 for ovarian cancer by study in White non-Hispanic subjects. (A) All ovarian cancer subtypes included. (B)
Analysis restricted to serous type ovarian cancers.
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under different prior probability scenarios (11). The FPRP
depends on the prior probability that a true association
exists, the observed level of significance (a) and the statistical
power to detect the OR of the alternative hypothesis at the
given a. As there are a large number of common SNPs in
the genome, the overall prior probability of association is
very low (,1 in 106). However, the prior probability that
rs4954956 is associated with ovarian cancer is more favour-
able as this is one of the best candidates from our breast
cancer GWAS and therefore a good candidate for ovarian
cancer susceptibility. The FPRPs for rs4954956 under
various prior probabilities and the power to detect the associ-
ation at our observed significance level a (assuming the true
effect size is equal to that observed) are presented in
Table 3. For example, assuming the prior probability to be 1
in 100 or 1 in 1000, the FPRP for association of rs4954956
with serous ovarian cancer would be 0.03 and 0.23, respect-
ively. This, along with the fact that results were indeed inde-
pendently replicated in the case–control validation studies
(Table 2), suggests that this association is robust (Table 3).
The evidence, however, is weaker for its association with all
types of ovarian cancer under the same prior probabilities.
Underlying population stratification is another explanation
for a spurious association. This occurs when allele frequencies
differ between population subgroups and cases and controls
are drawn differentially from those subgroups. To minimize
the impact of population stratification, analyses were restricted
to White subjects with non-Hispanic origin. If population stra-
tification were present, it is unlikely that the same degree of
stratification would be found in all 14 studies. We did not
observe any heterogeneity between different studies in the
initial or replication studies or the combined analysis for
rs4954956, thus providing evidence against substantial popu-
lation stratification or other study-specific biases.
If the observed association is confirmed, the SNP may be
directly causal or an indirect marker in linkage disequilibrium
with the real cause of malignancy. SNP rs4954956 is in an inter-
genic region situated ,7 kb upstream of the gene NXPH2,
which encodes the protein neurexophilin 2. NXPH2 is expressed
in kidney and brain and acts as a signalling molecule; it has also
been shown to be expressed in the ovary (http://
www.genecards.org/). It is a signalling molecule that resembles
neuropeptides and acts by binding to alpha-neurexins and poss-
ibly other receptors (12). However, it is not known whether
rs4954956 directly affects NXPH2 gene expression:
rs4954956 is not in a highly conserved region (http://
genome.ucsc.edu/cgi-bin/hgGateway) and various bioinfor-
matics tools such as SNAP (http://www.broad.mit.edu/mpg/
snap) did not reveal any variants associated with this SNP
(r2. 0.8) that have a putative function. It is possible that the
functional effects of rs4954956 are due to other, as yet uniden-
tified variants that are strongly correlated with this SNP.
Although breast cancer and ovarian cancer are both hormo-
nal related female cancers and share some common genetic
risk factors such as BRCA1/BRCA2 mutations, our data
suggest that the overlap between ovarian and breast cancer
susceptibility alleles is limited. We found no evidence of an
association of ovarian cancer risk with the remaining 10
breast GWAS hits tested. Gates et al. (13) recently reported
a null association for seven breast cancer susceptibility
alleles in two ovarian cancer case–control populations, five
of these alleles (i.e. rs2981582, rs3803662, rs889312,
rs3817198 and rs13281615) were also genotyped in our
study. Our meta-analysis pooling Gates et al.’s data together
with ours for these five SNPs appears to confirm that they
are not associated with ovarian cancer risks (data not
shown). By combined data from 14 ovarian cancer case–
control studies (5876 cases/9273 controls of non-Hispanic
origin), we were able to provide at least 90% power to
detect a co-dominant allele with a minor allele frequency of
0.27 that confers a relative risk of 1.1 at a Type 1 error of
0.05. However, our power to detect the alleles associated
with smaller ovarian cancer risks is low, and we cannot
exclude the possibility that the alleles investigated are associ-
ated with smaller risks for ovarian cancer.
In conclusion, we have found that rs4954956 is associated
with an increased ovarian cancer risk, but none of the top
six confirmed breast cancer susceptibility variants tested is
associated with ovarian cancer. Further work will be needed
to determine a functional rational for rs4954956 or any corre-
lated variants in causing ovarian cancer.
MATERIALS AND METHODS
Study subjects
Initial set. Six case–control studies contributed data to the
initial (stage1) analysis, including three studies from Europe
(SEA, MAL and UKO), two from the USA (STA and USC),
and one from Australia (AUS). Table 4 provides details for
each of the studies which followed a population-based case–
control design. Participation rates for cases and controls
were generally excellent, and included largely White non-
Hispanic women. In total, stage 1 comprised 2927 invasive
ovarian cases and 4143 controls.
Validation set. Eight case–control studies contributed data to
the validation set (stage 2) which included six studies from the
Table 3. False-positive report probability values for rs4954956
SNP Cancer type OR 95% CI Statistical powera P-value (a) Prior probability
0.25 0.1 0.01 0.001 0.0001
rs4954956 Ovarian 1.07 (1.01–1.13) 0.53 0.02 0.083 0.21 0.75 0.97 0.997
rs4954956 Serous ovarian 1.14 (1.07–1.22) 0.53 0.00017 0.001 0.003 0.029 0.23 0.75
Data highlighted with bold text are false-positive report probability (FPRP) ,0.5.
aUsing co-dominant model.
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USA (DOV, HOP, MAY, NCO, UCI, HAW) and two studies
from Europe (GER, POL). Stage 2 also included additional
samples from Australia (AUS) (413 cases/448controls),
UKO (180 cases/333 controls) and USC (323 cases/479 con-
trols) studies described above. Thus, the total validation set
comprised 4060 invasive ovarian cancer cases and 6308 con-
trols (Table 4).
These 14 case–control studies from OCAC contained a
total of 6987 invasive ovarian cancer cases and 10451 controls
when combined. Details of all these case–control studies have
been published (14,15).
To reduce the possibility of population stratification, the
analyses were limited to the 5876 cases and 9273 controls
who were of non-Hispanic White origin for whom genotype
information was available. All studies were approved by the
review boards and Ethics Committees of their parent insti-
tutions and written informed consent was obtained from all
participants.
Genotyping
Genotyping was performed at 11 different centres in 384-well
plate formats and all but one study (AUS) used TaqmanTM
7900HT Sequence Detection System according to the manu-
facturer’s instructions. The AUS study used iPlex technology
(Sequenom) for genotyping according to the manufacturer’s
instructions. Genotypes were determined using Allelic Dis-
crimination Sequence Detection Software (Applied Biosys-
tems, Warrington, UK). Assays were carried out in 384-well
plates and included at least 3% duplicate samples in each
plate for quality control. The six studies in the initial set
were genotyped either at the Department of Oncology, Univer-
sity of Cambridge or at the Gynaecological Oncology Unit,
University College London. The validation studies were gen-
otyped by the individual study centres. Each assay was
carried out using 10 ng DNA in a 5 ml reaction using
TaqMan universal PCR master mix, forward and reverse
primers and FAM and VIC labelled probes designed by
Applied Biosystems (ABI Assay-by-design). Details of
primer and probe sequences and assay conditions used for
each polymorphism analysed are available upon request.
Genotyping quality control. We compared genotype call
rates and concordance by study and overall. We used the fol-
lowing criteria as a measure of acceptable genotyping: (1)
.3% sample duplicates included; (2) concordance rate for
Table 4. Study description
Study Study name No.
controlsa








AUS Australian Cancer Study (ovarian
cancer)




DOV DOVE, Seattle (16) 796 (724) 584 (533) 332 (303) 1380 (1257) 91 USA: population based Case: 77%
Control: 69%








HOP HOPE study, Pittsburgh 672 (643) 300 (285) 169 (162) 972 (928) 95 USA: population based Case: 69%
Control: 81%




MAY Mayo Clinic Rochester Minnesota 467 (440) 337 (322) 206 (199) 804 (762) 95 USA: clinic-based Case: 84%
Control: 65%
NCO NCOCS 917 (726) 791 (616) 478 (375) 1708 (1342) 79 USA: population based Case: 70%
Control: 63%
POL POCS, Warsaw and Lodz Poland 625 (625) 264 (264) 118 (118) 889 (889) 100 Poland: population based Case: 71%
Control: 67%




STA GEOCS, Stanford 429 (367) 325 (287) 176 (159) 754 (654) 87 USA: population based Case: 75%
Control: 75%
UCI UC Irvine Ovarian Cancer Study,
California
536 (431) 339 (284) 183 (148) 875 (715) 82 USA: population based Case: 70%
Control: 80%




USC LAC-CCOC 754 (599) 631 (439) 380 (279) 1385 (1083) 75 USA: population based Case: 73%
Control: 73%
Total 10451 (9273) 6987 (5876) 3808 (3228) 17438 (15149) 87
AOCS, Australian Ovarian Cancer Study; DOVE, Diseases of the Ovary and their Evaluation Study; GOCS, German Ovarian Cancer Study; HOPE,
hormones and ovarian cancer prediction; MALOVA, Malignant Ovarian Cancer Study; NCOCS, North Carolina Ovarian Cancer Study; POCS, Polish
Ovarian Cancer Study; GEOCS, genetic epidemiology of ovarian cancer; UKOPS, United Kingdom Ovarian Cancer Population Study; LAC-CCOC, Los
Angeles County Case–Control Studies of Ovarian Cancer.
aNumbers in parentheses are the number of women who are non-Hispanic White origin.
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the duplicates 98%; (3) overall call rate (by study) .95%
and (4) call rates .90% for each individual 384-well plate.
The data for any SNP failing these criteria in any study
were excluded from the final analyses. The HWE among
White non-Hispanic controls was used to examine the
quality of genotyping. For any SNP that was out of HWE
(P , 0.05), the genotyping call rate was reviewed and the
data excluded if the genotype clusters was found to be subop-
timal. However, some studies with genotypes out of HWE
were included if their genotypes, based on clusters, were of
excellent quality. Genotyping consistency across labs was
also evaluated by genotyping a common panel of CEPH-Utah
trios including 90 individual DNA samples, five duplicate
samples and one negative control (http://ccr.coriell.org/
Sections/Search/
Panel_Detail.aspx?PgId=202&Ref=HAPMAPPT01). The con-
cordance of genotyping results between the centres was
required to be .98% in order for the genotype data to be
included. No attempt was made to repeat genotyping in
DNA samples that did not provide a clear genotype at
the first attempt resulting in variations in the number of
studies/samples that were successfully genotyped for each
polymorphism.
Statistics
Deviation of genotype frequencies from those expected under
HWE was assessed by x2 tests with one degree of freedom
(1df) for each study of controls as part of the genotyping
quality control. The primary test of association was the com-
parison of genotype frequencies in cases and controls using
a test for gene-dose effect for each SNP through an interval
variable with three levels: 0, 1, 2; one assigned to each geno-
type. This was done using unconditional logistic regression
stratified by study. OR for allele dosage and associated 95%
CI were also estimated by unconditional logistic regression.
We tested for heterogeneity between study strata by compar-
ing logistic regression models with and without a
genotype-stratum interaction term using likelihood ratio
tests. A subgroup analysis was used to compare genotype-
specific risks by disease subgroup with the controls. We
limited subgroup analysis to the serous histology type as the
number of cases diagnosed with other subtypes was low.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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